SunTrust analyst Edward Nash reiterated a Buy rating and $19.00 price target on CymaBay Therapeutic (NASDAQ: CBAY), saying the sell-off ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE